Cryo-Cell International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022
July 11, 2022 at 10:01 pm
Share
Cryo-Cell International, Inc. reported earnings results for the second quarter and six months ended May 31, 2022. For the second quarter, the company reported revenue was USD 7.63 million compared to USD 7.21 million a year ago. Net income was USD 0.634719 million compared to USD 1.17 million a year ago. Basic earnings per share from continuing operations was USD 0.08 compared to USD 0.15 a year ago. Diluted earnings per share from continuing operations was USD 0.07 compared to USD 0.14 a year ago.
For the six months, revenue was USD 14.89 million compared to USD 14.07 million a year ago. Net income was USD 1.47 million compared to USD 1.86 million a year ago. Basic earnings per share from continuing operations was USD 0.17 compared to USD 0.24 a year ago. Diluted earnings per share from continuing operations was USD 0.17 compared to USD 0.23 a year ago.
Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 235,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
CRYO-CELL INTERNATIONAL, INC. 
